STUTTGART, Germany I August 06, 2024 I La Merie Publishing released its newest product reviewing the pipeline of immunotherapy candidates targeting the CD47-SIRPalpha pathway:
CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
- Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for investigational immunotherapies targeting CD47 or SIRP-alpha (prerequisite: access to internet).
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
The phagocytic activity of macrophages is regulated by both activating (“eat me”) and inhibitory (“don’t eat me”) signals. CD47 serves as a critical “don’t eat me” signal inhibiting phagocytosis by binding to signal regulatory protein alpha (SIRPα) on the surface of macrophages. The CD47-SIRPα interaction represents an important mechanism by which malignant cells evade macrophage-mediated destruction. CD47 is overexpressed in numerous hematological cancers and solid tumors, and high CD47 expression correlates with more aggressive disease and poorer clinical outcomes. Preclinical studies have shown that interrupting the CD47-SIRPα signaling pathway promotes anti-tumor activity against human cancers, both in vitro and in vivo. Thus, blocking CD47 has emerged as a promising therapeutic strategy with early clinical data demonstrating benefit to cancer patients.
Dual function molecules are designed to 1) bind CD47 and neutralize its suppressive signal, and 2) deliver a pro-phagocytic (“eat me”) signal through the Fc region, which binds to activating Fc receptors on the surface of macrophages. It is believed that the combination of these two events – blockade of the negative CD47 “don’t eat me” signal and delivery of a positive Fc “eat me” signal – is a particularly effective way to enable macrophages to destroy tumor cells. Thus, there are differences to be expected whether the Fc is of the IgG1 or IgG4 isotype or even inert (inactivated Fc).
However, development of CD47 antibody as a cancer therapy is hampered by its hematologic side effects, such as severe anemia, caused by natural binding of CD47 antibody to red blood cells. A differentiation factor among competitor molecules is the virtue of not binding or reduced binding to CD47 on human red blood cells. This lowers the risk of serious anemia in patients, avoids the removal of the drug from the circulation by red blood cells (“antigen sink effect”) and minimizes interference with laboratory blood typing tests.
The development pipeline is full of directly acting specific, bispecific or multispecific CD47 and SIRPα inhibitors. Drug modalities include monoclonal antibodies, fusion proteins, protein biologics, RNA/mRNA or small molecules. More than 20 distinct molecules targeting the CD47-SIRPα pathway are in clinical development.
The report “CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/cd47-and-sirp-alpha-targeted-immunotherapy-pipeline-review/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 4,835
STUTTGART, Germany I August 06, 2024 I La Merie Publishing released its newest product reviewing the pipeline of immunotherapy candidates targeting the CD47-SIRPalpha pathway:
CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
- Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for investigational immunotherapies targeting CD47 or SIRP-alpha (prerequisite: access to internet).
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
The phagocytic activity of macrophages is regulated by both activating (“eat me”) and inhibitory (“don’t eat me”) signals. CD47 serves as a critical “don’t eat me” signal inhibiting phagocytosis by binding to signal regulatory protein alpha (SIRPα) on the surface of macrophages. The CD47-SIRPα interaction represents an important mechanism by which malignant cells evade macrophage-mediated destruction. CD47 is overexpressed in numerous hematological cancers and solid tumors, and high CD47 expression correlates with more aggressive disease and poorer clinical outcomes. Preclinical studies have shown that interrupting the CD47-SIRPα signaling pathway promotes anti-tumor activity against human cancers, both in vitro and in vivo. Thus, blocking CD47 has emerged as a promising therapeutic strategy with early clinical data demonstrating benefit to cancer patients.
Dual function molecules are designed to 1) bind CD47 and neutralize its suppressive signal, and 2) deliver a pro-phagocytic (“eat me”) signal through the Fc region, which binds to activating Fc receptors on the surface of macrophages. It is believed that the combination of these two events – blockade of the negative CD47 “don’t eat me” signal and delivery of a positive Fc “eat me” signal – is a particularly effective way to enable macrophages to destroy tumor cells. Thus, there are differences to be expected whether the Fc is of the IgG1 or IgG4 isotype or even inert (inactivated Fc).
However, development of CD47 antibody as a cancer therapy is hampered by its hematologic side effects, such as severe anemia, caused by natural binding of CD47 antibody to red blood cells. A differentiation factor among competitor molecules is the virtue of not binding or reduced binding to CD47 on human red blood cells. This lowers the risk of serious anemia in patients, avoids the removal of the drug from the circulation by red blood cells (“antigen sink effect”) and minimizes interference with laboratory blood typing tests.
The development pipeline is full of directly acting specific, bispecific or multispecific CD47 and SIRPα inhibitors. Drug modalities include monoclonal antibodies, fusion proteins, protein biologics, RNA/mRNA or small molecules. More than 20 distinct molecules targeting the CD47-SIRPα pathway are in clinical development.
The report “CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/cd47-and-sirp-alpha-targeted-immunotherapy-pipeline-review/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 4,835
